Zacks Research Has Bearish Outlook for Chemours Q3 Earnings

Key Points

• Zacks Research has downgraded Chemours' Q3 2025 earnings per share (EPS) forecast from $0.48 to $0.33, indicating a deterioration in expected performance.
• Despite a recent quarterly earnings beat, Chemours reported a negative net margin of 7.19% and has set a full-year earnings estimate of $2.03 per share.
• The company also announced a quarterly dividend of $0.0875, representing a yield of 2.3%, although its dividend payout ratio is currently negative at -12.50%.

The Chemours Company (NYSE:CC - Free Report) - Research analysts at Zacks Research lowered their Q3 2025 earnings estimates for shares of Chemours in a report released on Monday, August 18th. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings of $0.33 per share for the quarter, down from their prior estimate of $0.48. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q1 2026 earnings at $0.37 EPS, Q2 2026 earnings at $0.66 EPS, Q3 2026 earnings at $0.77 EPS, FY2026 earnings at $2.20 EPS and FY2027 earnings at $2.62 EPS.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

CC has been the topic of several other research reports. Barclays lowered their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 28th. Royal Bank Of Canada increased their price objective on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. Mizuho increased their price objective on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 15th. UBS Group cut their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Morgan Stanley cut their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Chemours presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.38.

Chemours Stock Performance

NYSE:CC traded up $1.1930 during mid-day trading on Wednesday, reaching $15.3430. The company's stock had a trading volume of 4,286,614 shares, compared to its average volume of 4,460,065. Chemours has a 12-month low of $9.13 and a 12-month high of $22.38. The firm's fifty day moving average price is $12.90 and its two-hundred day moving average price is $12.96. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The stock has a market cap of $2.30 billion, a P/E ratio of -5.48 and a beta of 1.61.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.0875 per share. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's dividend payout ratio is -12.50%.

Insider Buying and Selling

In related news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer owned 191,546 shares in the company, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Damian Gumpel acquired 7,822 shares of the stock in a transaction on Tuesday, June 3rd. The stock was bought at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the transaction, the insider owned 131,701 shares in the company, valued at approximately $1,310,424.95. This represents a 6.31% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 25,290 shares of company stock worth $250,437. 0.47% of the stock is owned by insiders.

Institutional Trading of Chemours

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Chemours in the 2nd quarter worth $116,000. Nomura Holdings Inc. acquired a new stake in shares of Chemours in the 2nd quarter worth $515,000. Public Sector Pension Investment Board grew its holdings in shares of Chemours by 7.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 510,312 shares of the specialty chemicals company's stock worth $5,843,000 after purchasing an additional 36,473 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Chemours by 18.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,123 shares of the specialty chemicals company's stock worth $139,000 after purchasing an additional 1,925 shares during the period. Finally, Duquesne Family Office LLC purchased a new position in shares of Chemours during the 2nd quarter worth $4,830,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.